Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis
August 16, 2022 10:54 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures. This round includes...
Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer
February 02, 2022 08:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced...
BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference
January 13, 2022 08:00 ET
|
BlueJay Therapeutics
SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief...